**Table S1. Number of participants with missing data.**

|                  | Total | Patients with CKD | Healthy Controls | CKD stage 2 | CKD stage 3 | CKD stage 4 | CKD stage 5 | HD New starters | Established HD | Transplant |
|------------------|-------|-------------------|-----------------|-------------|-------------|-------------|-------------|----------------|----------------|------------|
| BMI              | 10    | 9                 | 1               | 0           | 5           | 1           | 1           | 1              | 0              | 1          |
| Urea             | 9     | 2                 | 7               | 1           | 0           | 0           | 0           | 0              | 0              | 0          |
| INR              | 21    | 12                | 9               | 0           | 5           | 3           | 2           | 0              | 0              | 2          |
| APTT             | 21    | 12                | 9               | 0           | 5           | 3           | 2           | 0              | 0              | 2          |
| HGB, PCV and Platelets | 7     | 0                 | 7               | 0           | 0           | 0           | 0           | 0              | 0              | 0          |
| ADP, ASPI and TRAP tests | 4    | 4                 | 0               | 0           | 2           | 0           | 1           | 0              | 1              | 0          |
| Lag time, Peak, ttP and ETP | 1   | 1                 | 0               | 0           | 0           | 0           | 0           | 0              | 1              | 0          |
| α-2 antiplasmin, PAI-1, TAT, D-dimer and ICAM-1 | 1     | 1                 | 0               | 0           | 0           | 0           | 1           | 0              | 0              | 0          |

**ROTEM INTEM**

|                  | Total | Patients with CKD | Healthy Controls | CKD stage 2 | CKD stage 3 | CKD stage 4 | CKD stage 5 | HD New starters | Established HD | Transplant |
|------------------|-------|-------------------|-----------------|-------------|-------------|-------------|-------------|----------------|----------------|------------|
| CT, CFT, α-angle, MCF, ML | 2     | 2                 | 0               | 0           | 1           | 0           | 0           | 1              | 0              | 0          |
| A5, A10, A20, LI30 | 3     | 3                 | 0               | 0           | 1           | 0           | 0           | 2              | 0              | 0          |

**ROTEM EXTEM**

|                  | Total | Patients with CKD | Healthy Controls | CKD stage 2 | CKD stage 3 | CKD stage 4 | CKD stage 5 | HD New starters | Established HD | Transplant |
|------------------|-------|-------------------|-----------------|-------------|-------------|-------------|-------------|----------------|----------------|------------|
| CT, CFT, α-angle, A5, MCF, ML | 2   | 2                 | 0               | 0           | 1           | 0           | 0           | 1              | 0              | 0          |
| A10, A20, LI30 | 3     | 3                 | 0               | 0           | 1           | 0           | 0           | 2              | 0              | 0          |

**ROTEM FIBTEM**

|                  | Total | Patients with CKD | Healthy Controls | CKD stage 2 | CKD stage 3 | CKD stage 4 | CKD stage 5 | HD New starters | Established HD | Transplant |
|------------------|-------|-------------------|-----------------|-------------|-------------|-------------|-------------|----------------|----------------|------------|
| MCF              | 3     | 3                 | 0               | 0           | 1           | 0           | 0           | 2              | 0              | 0          |

CKD indicates Chronic Kidney Disease; HD, Haemodialysis; BMI, Body Mass Index; INR, International Normalisation Ratio; APTR, Activated Partial Thromboplastin Ratio; HGB, Haemoglobin; PCV, Packed Cell Volume; ADP, Adenosine Diphosphate; ASPI, Aspirin; and TRAP, Thrombin Receptor Activating Peptide; ttP, time to Peak; ETP, Endogenous Thrombin Potential; PAI-1, Platelet Activator Inhibitor-1; TAT, Thrombin Antithrombin; ICAM-1, Intercellular Adhesion Molecule-1; ROTEM, Rotational Thromboelastometry; CT, Clotting time; CFT, Clot Formation Time; MCF, Maximum Clot firmness; ML, Maximum Lysis; LI30, Lysis index at 30 minutes